Aviva Capital Partners (ACP) and Populate have secured two new oncology companies as tenants at the Innovation Gateway life sciences incubator at the heart of the London Cancer Hub.
Kindling Bio, a start-up focused on developing cancer gene therapies for children, and cancer diagnostics company Beckman Coulter have signed for self-contained lab space at the incubator on a flexible basis.
The incubator, which provides 3,500 sq ft of lab space over two floors, is now 85% full. It forms part of the London Cancer Hub where plans have been submitted by ACP and Socius for a circa 1m sq ft development featuring lab and R&D facilities.
The Innovation Gateway was opened by Sutton Council in 2021. ACP has taken on the management of the site and appointed Populate to oversee the delivery of enhanced facilities including new meeting spaces and a marketing suite.
Sophie White, head of regeneration at Aviva Capital Partners, said: “The Innovation Gateway, which provides space for fast-growing oncology companies to collaborate and grow, is a microcosm of what can be achieved at scale at the London Cancer Hub. Our vision is to help the UK get ready for the future by delivering best-in-class lab and R&D space of all sizes that will enable life sciences companies to work closely with the Institute of Cancer Research and Royal Marsden Foundational Trust, and unlock further innovation in cancer treatment.”
Olaide Oboh, managing director of Populate added: “The Innovation Gateway is at the heart of the ecosystem at London Cancer Hub and we are proud to be working with Aviva Capital Partners to provide a launchpad for fast-growing businesses in the oncology space. The workspace is vital but we are equally focused on the spaces between the buildings, and how we can create a more connected and inclusive district where people want to work, meet, socialise and share ideas.”
